NDA 021256 · Chirhoclin
Chirhostim
Secretin Synthetic Human · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 18, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Apr 9, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
35
10 Phase 3, 2 recruiting
FAERS reports
2
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2025.
INDICATIONS AND USAGE ChiRhoStim ® is indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. gastrin secretion to aid in the diagnosis of gastrinoma, and pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). ChiRhoStim® is a secretin class hormone indicated for stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction (1) gastrin secretion to aid in the diagnosis of gastrinoma (1) pancreatic secretions to facilitate the identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP) (1)
Mechanism: Mechanism of Action 12.1 Mechanism of Action The primary action of ChiRhoStim ® is to stimulate pancreatic ductal cells to secrete pancreas fluid in large volumes that contain bicarbonate. Secretin is a hormone that is normally released from the duodenum upon exposure of the proximal intestinal lumen to gastric acid, fatty acids and amino acids. Secretin is released from enterochromaffin cells in the intestinal mucosa. Secretin receptors have been identified in the pancreas, stomach, liver, colon and other tissues. When secretin binds to secretin receptors on pancreatic duct cells it opens...
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
- CHIRHOSTIM · SECRETIN SYNTHETIC HUMAN 16MCG/VIAL · FOR SOLUTION, INTRAVENOUS · Prescription
- CHIRHOSTIM · SECRETIN SYNTHETIC HUMAN 40MCG/VIAL · FOR SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Secretin Synthetic Human" as an intervention, any sponsor and status, largest first.
- The Cancer of the Pancreas Screening-5 CAPS5)StudyPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT02000089 · 9,000 participants (planned) · Start Jan 6, 2014 · Primary completion Dec 2028
Drug: Secretin · For: Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation and 2 more
Sites: New Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
- Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the PancreasPivotal-lookingCompleted
Repligen CorporationIndustry
NCT00660335 · 258 participants · Start Mar 2008 · Primary completion Oct 2009
Drug: RG1068 (synthetic human secretin) · For: Pancreatitis
- The Effects of Bariatric Surgeries on Glucose MetabolismPivotal-lookingRecruiting
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT02823665 · 200 participants (planned) · Start Jul 2015 · Primary completion Aug 2026
Drug: Exendin-(9-39); Atropine · For: Post Bariatric Surgery; Gastric Bypass; Sleeve Gastrectomy and 1 more
Sites: San Antonio, Texas · 2 sites in all
- Imaging Biomarkers of Pancreatic Function and DiseaseEnrolling by invitation
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT05659147 · 195 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Secretin · For: Pancreatitis; Diabetes Mellitus
Sites: Cincinnati, Ohio
- Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic ResectionPivotal-lookingCompleted
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT02160808 · 170 participants · Start May 2014 · Primary completion Sep 21, 2019
Drug: Secretin; Placebo · For: Injury of Body of Pancreas
Sites: Lebanon, New Hampshire
- Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.Pivotal-lookingStatus unknown
Fundacion Clinic per a la Recerca BiomédicaAcademic, hospital or other
NCT05914077 · 140 participants (planned) · Start Sep 13, 2023 · Primary completion Jan 2025
Drug: Secretin · For: Intraductal Papillary Mucinous Neoplasm of Pancreas
Sites: Barcelona, Spain
- Secretin for the Treatment of AutismPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00065962 · 85 participants · Start Jun 1999
Drug: secretin, synthetic porcine; secretin, biologically derived porcine · For: Autism
Sites: Denver, Colorado; Seattle, Washington
- A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA MarkersPivotal-lookingCompleted
ChiRhoClin, Inc.Industry
NCT01087801 · 64 participants · Start Oct 2007 · Primary completion Nov 2009
Drug: ChiRhoStim; Placebo · For: Pancreatic Disease
Sites: St Louis, Missouri
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- muscle spasms1
- product storage error1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2019 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Chirhoclin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.